Abstract
Gliflozins are antidiabetic drugs improving the compensation of diabetes by increasing glycosuria due to sodium-glucose cotransporter 2 (SGLT2) inhibition in the proximal tubule of kidneys. As early as in the results of the first studies, it was shown that in addition to the improvement of diabetes compensation, weight reduction and lowering the blood pressure, gliflozins can also have significant positive effect in patients with cardiovascular complications, heart failure and diabetic kidney disease.
In the context of heart failure, the most complete and convincing results are present in patients with heart failure and reduced ejection fraction where the improvement of clinical status and lowered hospitalization rate in this indication was proven in patients with type 2 diabetes but also in non-diabetic patients. Therefore, two gliflozins with completed clinical trials in patients with heart failure and reduced ejection fraction - dapagliflozin and empagliflozin - have a new indication for administration in the presence of this type of heart failure, regardless of the presence of diabetes.
In this article, we summarize the newest evidence regarding the usage of gliflozins in patients with heart failure and we discuss the perspectives of their further application in patients with this diagnosis.